Robin Zon, Chair ASCO Society Board, shared a post on LinkedIn:
“Honored to be at JSMO!
Was able to attend first discussion today during Presidential Session 1 featuring ASCO Board member, Jason Westin presenting the SUNMO Trial for chemo free treatment for relapsed LBCL – impressive data and…announcement that this regimen approved in Japan March 23,2026!
These are fantastic study results as now there is a great option available – especially for patients with various barriers to care.”
Other articles about JSMO on OncoDaily.
